Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the submission of an application for a Phase III clinical trial of IMM0306, a bispecific molecule targeting CD47 and CD20, for the treatment of follicular lymphoma. This development marks a significant step as IMM0306 is the first dual-targeting bispecific molecule of its kind to reach the clinical stage globally, potentially enhancing the company’s position in the oncology market by offering improved therapeutic outcomes for patients.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. operates in the biopharmaceutical industry, focusing on developing innovative cancer therapies. The company specializes in creating bispecific molecules, with a market focus on improving therapeutic outcomes for cancer patients.
Average Trading Volume: 3,422,253
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.98B
For an in-depth examination of 1541 stock, go to TipRanks’ Overview page.